AstraZeneca : AstraZeneca approaches Gilead about potential link-up
>This would be the biggest deal in the sector’s history - According to Bloomberg (Sunday, 7 June), AstraZeneca apparently approached Gilead last month with a view to a merger in what would be the biggest pharma deal in history. AstraZeneca has a market capitalisation of $ 141bn and Gilead $ 96bn. Revenues for the new entity would exceed $ 53bn (2021e) and would be generated entirely by prescription drugs, making AstraZeneca one of the two biggest prescription pharma g...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.